Transcode Net Debt from 2010 to 2026

RNAZ Stock

USD 8.01 0.08 1.01%

Transcode Therapeutics Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt will likely drop to about -5.5 M in 2026. Net Debt is the total debt of Transcode Therapeutics minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2019-12-31

Previous Quarter

-7.4 M

Current Value

-2.8 B

Quarterly Volatility

617.6 M

Covid

Check Transcode Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Transcode Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 315.4 K, Interest Expense of 29.3 K or Selling General Administrative of 6.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Transcode financial statements analysis is a perfect complement when working with Transcode Therapeutics Valuation or Volatility modules.

Build AI portfolio with Transcode Stock

Check out the analysis of Transcode Therapeutics Correlation against competitors.

For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.

Latest Transcode Therapeutics' Net Debt Growth Pattern

Below is the plot of the Net Debt of Transcode Therapeutics over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Transcode Therapeutics' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Transcode Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Transcode Net Debt Regression Statistics

	Arithmetic Mean	(2,366,033)
	Geometric Mean	906,019
	Coefficient Of Variation	(226.96)
	Mean Deviation	3,575,018
	Median	258,921
	Standard Deviation	5,370,005
	Sample Variance	28.8T
	Range	22.1M
	R-Value	(0.49)
	Mean Square Error	23.2T
	R-Squared	0.24
	Significance	0.04
	Slope	(526,138)
	Total Sum of Squares	461.4T

Transcode Net Debt History

	2026	-5.5 M
	2025	-5.2 M
	2024	-5.8 M
	2023	-2.3 M
	2022	-5 M
	2021	-20.8 M
	2020	1.3 M

Other Fundumenentals of Transcode Therapeutics

Net Debt To E B I T D A

Transcode Therapeutics Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Accounts Payable	Long Term Debt	Net Invested Capital	Capital Stock	Net Working Capital	Short Term Investments	Deferred Long Term Liab	Current Deferred Revenue	Property Plant Equipment	Net Receivables
Total Assets		0.82	0.97	-0.99	-0.46	0.45	1.0	0.39	-0.03	0.68	0.7	0.81	0.43	0.97	0.39	-0.23	-0.38	-0.23	-0.23
Total Stockholder Equity	0.82		0.91	-0.86	0.08	-0.15	0.82	0.45	0.46	0.26	0.27	1.0	0.72	0.87	-0.13	0.19	0.19	0.19	0.19
Net Tangible Assets	0.97	0.91		-0.99	-0.31	0.26	0.97	0.35	0.17	0.52	0.52	0.89	0.47	0.98	0.23	-0.15	-0.22	-0.15	-0.15
Net Debt	-0.99	-0.86	-0.99		0.38	-0.37	-0.99	-0.37	-0.08	-0.59	-0.6	-0.85	-0.47	-0.99	-0.3	0.2	0.3	0.2	0.2
Retained Earnings	-0.46	0.08	-0.31	0.38		-0.91	-0.45	0.17	0.82	-0.82	-0.77	0.11	0.4	-0.29	-0.96	0.59	0.94	0.59	0.59
Total Liab	0.45	-0.15	0.26	-0.37	-0.91		0.44	-0.04	-0.75	0.73	0.75	-0.15	-0.37	0.32	0.87	-0.75	-0.95	-0.75	-0.75
Total Current Assets	1.0	0.82	0.97	-0.99	-0.45	0.44		0.39	-0.01	0.66	0.69	0.82	0.44	0.97	0.37	-0.23	-0.36	-0.23	-0.23
Short Term Debt	0.39	0.45	0.35	-0.37	0.17	-0.04	0.39		0.26	0.04	0.32	0.52	0.41	0.44	-0.22	0.18	0.24	0.18	0.18
Common Stock	-0.03	0.46	0.17	-0.08	0.82	-0.75	-0.01	0.26		-0.71	-0.62	0.47	0.41	0.19	-0.9	0.47	0.82	0.47	0.47
Accounts Payable	0.68	0.26	0.52	-0.59	-0.82	0.73	0.66	0.04	-0.71		0.86	0.24	0.16	0.49	0.88	-0.36	-0.76	-0.36	-0.36
Long Term Debt	0.7	0.27	0.52	-0.6	-0.77	0.75	0.69	0.32	-0.62	0.86		0.28	0.05	0.54	0.73	-0.3	-0.66	-0.3	-0.3
Net Invested Capital	0.81	1.0	0.89	-0.85	0.11	-0.15	0.82	0.52	0.47	0.24	0.28		0.72	0.87	-0.16	0.19	0.21	0.19	0.19
Capital Stock	0.43	0.72	0.47	-0.47	0.4	-0.37	0.44	0.41	0.41	0.16	0.05	0.72		0.47	-0.3	0.39	0.41	0.39	0.39
Net Working Capital	0.97	0.87	0.98	-0.99	-0.29	0.32	0.97	0.44	0.19	0.49	0.54	0.87	0.47		0.19	-0.2	-0.23	-0.2	-0.2
Short Term Investments	0.39	-0.13	0.23	-0.3	-0.96	0.87	0.37	-0.22	-0.9	0.88	0.73	-0.16	-0.3	0.19		-0.61	-0.95	-0.61	-0.61
Deferred Long Term Liab	-0.23	0.19	-0.15	0.2	0.59	-0.75	-0.23	0.18	0.47	-0.36	-0.3	0.19	0.39	-0.2	-0.61		0.8	1.0	1.0
Current Deferred Revenue	-0.38	0.19	-0.22	0.3	0.94	-0.95	-0.36	0.24	0.82	-0.76	-0.66	0.21	0.41	-0.23	-0.95	0.8		0.8	0.8
Property Plant Equipment	-0.23	0.19	-0.15	0.2	0.59	-0.75	-0.23	0.18	0.47	-0.36	-0.3	0.19	0.39	-0.2	-0.61	1.0	0.8		1.0
Net Receivables	-0.23	0.19	-0.15	0.2	0.59	-0.75	-0.23	0.18	0.47	-0.36	-0.3	0.19	0.39	-0.2	-0.61	1.0	0.8	1.0

Click cells to compare fundamentals

About Transcode Therapeutics Financial Statements

Transcode Therapeutics investors use historical fundamental indicators, such as Transcode Therapeutics' Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Transcode Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	-5.2 M	-5.5 M
Net Debt To EBITDA	0.32	0.34

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

GOOG	Alphabet Inc Class C
V	Visa Class A
MSFT	Microsoft

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Transcode Net Debt from 2010 to 2026

Latest Transcode Therapeutics' Net Debt Growth Pattern

Transcode Net Debt Regression Statistics

Transcode Net Debt History

Other Fundumenentals of Transcode Therapeutics

Transcode Therapeutics Net Debt component correlations

About Transcode Therapeutics Financial Statements

Also Currently Popular

Additional Tools for Transcode Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY